Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD

The entire JAK inhibitor family of medicines is feeling the ripple effects from a safety signal flagged for Pfizer’s Xeljanz. Now, the first marketed drug in the class is encountering increased scrutiny from the FDA.